Idecabtagene Vicleucel represents the only cell therapy approved for multiple myeloma Approval of Idecabtagene Vicleucel is based on the pivotal KarMMa trial of patients worldwide, including five European countries, which […]

Réf. :HematoStat.net ; 1 (1) : V18 Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner […]

Réf. :HematoStat.net ; 1 (1) : V16 Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy […]

Réf. :HematoStat.net ; 1 (1) : V15 Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Doi 10.1038/s41467-021-23376-6.

Réf. :HematoStat.net ; 1 (1) : V13 Yang Y, Wang Y, Liu X, He X, Zhang LL, Wu G, Qu BL, Qian LT, Hou XR, Zhang FQ, Qiao XY, Wang […]

Réf. :HematoStat.net ; 1 (1) : V11 Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Doi 10.3390/cancers13092095.

Réf. :HematoStat.net ; 1 (1) : V10 Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Doi 10.1182/bloodadvances.2020004173